Full Text View
Tabular View
Study Results
Related Studies
Long-Term Safety of Ospemifene 60 mg Oral Daily Dose for the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women Without a Uterus
This study has been completed.
Study NCT01586364   Information provided by Shionogi Inc.

First Received on April 18, 2012.   Last Updated on May 21, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
More general conditions related to this trial
Interventions listed in this trial
Sponsors listed in this trial